Regulation & law · 21/09/1995Updated: 10/18/2026 · 1 min read
Bristol Myers Squibb Seeks Extension of Exclusive Patent License for Opdivo
Summary
Bristol Myers Squibb has submitted a notice to the U.S. Patent and Trademark Office requesting a prospective extension of its exclusive patent license for Opdivo, a cancer treatment medication.